Clinical trials: Psoriasis Arthritis
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia
The main objective of this post-authorization safety study is to assess healthcare professionals' awareness, knowledge, and behavior related to receipt and reading of the Direct Healthcare Professional Communication and…
- Trial name
- ARAVA PASS (NCT06714461)
- Testing
- Leflunomide
- Where
- France
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Sanofi
Autoimmune Diseases, Rheumatoid Arthritis (RA)
A Trial of Academic Detailing to Promote Prescribing of Biosimilars
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1.
- Conditions
- Autoimmune Diseases, Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Psoriasis (PsO)
- Trial name
- NCT07221890
- Testing
- Offered an academic detailing session, Standard-of-care outreach from the insurance plan
- Where
- 2 sites in United States
- Volunteers
- 1,325 people
- Sponsor
- Brigham and Women's Hospital
Psoriatic Arthritis, Upadacitinib
Upadacitinib Versus IL-17 Inhibitors in Patients With Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease with heterogeneous musculoskeletal and dermatologic manifestations, leading to significant functional impairment and reduced quality of life.
- Conditions
- Psoriatic Arthritis, Upadacitinib, Interleukin-17 Inhibitors
- Trial name
- UVIPWP (NCT07386717)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking University First Hospital
Arthritis, Rheumatoid, Colitis, Ulcerative
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
The purpose of this study is to learn about the safety of the safety of the study medicine called infliximab for the possible treatment of rheumatoid arthritis (RA), ulcerative colitis (UC, Crohn's disease, or psoriasis.
- Conditions
- Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis
- Trial name
- NCT05796245
- Where
- Japan
- Volunteers
- 2,207 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid, Crohn Disease
A Long-term Safety Study of Infliximab (Remicade)
This is a study evaluating the long-term safety of infliximab (Remicade)
- Conditions
- Arthritis, Rheumatoid, Crohn Disease, Psoriasis
- Trial name
- NCT00261976
- Testing
- Infliximab (Remicade)
- Where
- 205 sites in United States, Argentina and 17 more
- Volunteers
- 2,971 people
- Sponsor
- Centocor, Inc.
Psoriatic Arthritis
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
While many studies examine Nonalcoholic fatty liver disease (NAFLD), little is known about its progression to high-risk nonalcoholic steatohepatitis (NASH) in PsA patients.
- Trial name
- NCT06586281
- Testing
- Guselkumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Diego
Arthritis, Psoriatic
Study Evaluating the Safety of Enbrel (Etanercept)
The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.
- Trial name
- NCT00683384
- Testing
- Etanercept (Enbrel)
- Where
- Philippines
- Volunteers
- 93 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals